Pharming Group N.V. today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The presentation slides from today’s AGM are available on the Company’s website.

On 16 May each year, hereditary angioedema (HAE) patient organizations from around the world, led by the HAEi, the international umbrella organization for the world’s HAE patient groups, come together to support awareness of HAE; a rare, potentially life-threatening condition. hae day :-) aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need to lead a better life.

Pharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.

Pharming Group N.V. announces that the Notice to Convene for its Annual General Meeting of Shareholders has been uploaded on its website. Pharming’s upcoming Annual General Meeting will be held at the Holiday Inn (Haagse Schouwweg 10, 2332 KG Leiden, The Netherlands) on 22 May 2019 at 14:00 CEST.

Pharming Group N.V. announces that following the Company’s announcement on 29 March 2019, it has completed its investment of €1.6 million in cash and conversion of €2.5 million of prepayments into new equity in its Fill & Finish partner BioConnection BV, which manufactures the sterile sealed vials of Pharming’s product RUCONEST® from the purified drug substance.

Pharming Group N.V. announces publication of its Annual Report for the financial year ended 31 December 2018. The Company also announces that it has made a provisional commitment to invest up to €1.6 million in cash and convert €2.5 million of prepayments into equity in its fill & finish partner BioConnection BV, which manufactures the final sealed vials of Pharming’s product RUCONEST® from the purified drug substance.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2018.

Pharming Webinar: Jaarcijfers 2018 donderdag 7 maart 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!

Pharming Group N.V. announced today that an abstract was presented this week at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, CA. Additionally, Pharming is pleased to announce sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAAI Lectureship.